ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) today announced that all 72 patients have been enrolled in the Company’s Phase 2 clinical trial with RGN-259 for the treatment of dry eye syndrome. The Company expects all patients will complete treatment by September 23rd and preliminary data from the study is scheduled to be available in October.
